Skip to content

Intra-Cellular Therapies, Inc.

Delisted

CIK 1567514fmd_0ZRR755B0TFWK74K5EPG16XNX4Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2012 to Dec 31, 2024, 50 periods

Latest annual · FY2024

Millions
Total revenues
681
Operating income
(117)
Net income
(75)
Free cash flow
(73)

Latest quarter · Q4 FY2024

Millions
Total revenues
199
Operating income
(29)
Net income
(17)
Free cash flow
(13)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2021 to FY2024
+101.0%
Revenue, 5 yearsFY2019 to FY2024
+545.8%
Net income, 5 yearsFY2019 to FY2024
n/m

Intra-Cellular Therapies, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2024FY2023ChangeSource
Revenue$680.9 million$464.4 million+46.6%10-K 2025-02-21 · proof
Operating income-$116.7 million-$159.4 million10-K 2025-02-21 · proof
Net income-$74.7 million-$139.7 million10-K 2025-02-21 · proof
Cash from operating activities-$73.2 million-$124.2 million10-K 2025-02-21 · proof
Free cash flow-$73.5 million-$124.5 million10-K 2025-02-21 · proof
Total assets$1.4 billion$728.3 million+87.7%10-K 2025-02-21 · proof
Total liabilities$218.5 million$136.9 million+59.6%10-K 2025-02-21 · proof
Cash and cash equivalents$306.9 million$147.8 million+107.7%10-K 2025-02-21 · proof
What was Intra-Cellular Therapies, Inc.'s revenue in fiscal 2024?
Intra-Cellular Therapies, Inc. reported revenue of $680.9 million for fiscal 2024 (the year ended Dec 31, 2024), against $464.4 million the year before (+46.6%). Source: the 10-K filed with the SEC on Feb 21, 2025. SEC
What was Intra-Cellular Therapies, Inc.'s operating income in fiscal 2024?
Intra-Cellular Therapies, Inc. reported operating income of -$116.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$159.4 million the year before. Source: the 10-K filed with the SEC on Feb 21, 2025. SEC
What was Intra-Cellular Therapies, Inc.'s net income in fiscal 2024?
Intra-Cellular Therapies, Inc. reported net income of -$74.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$139.7 million the year before. Source: the 10-K filed with the SEC on Feb 21, 2025. SEC
What was Intra-Cellular Therapies, Inc.'s cash from operating activities in fiscal 2024?
Intra-Cellular Therapies, Inc. reported cash from operating activities of -$73.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$124.2 million the year before. Source: the 10-K filed with the SEC on Feb 21, 2025. SEC
What was Intra-Cellular Therapies, Inc.'s free cash flow in fiscal 2024?
Intra-Cellular Therapies, Inc. reported free cash flow of -$73.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$124.5 million the year before. Source: the 10-K filed with the SEC on Feb 21, 2025. SEC
What are Intra-Cellular Therapies, Inc.'s total assets?
As of Dec 31, 2024, Intra-Cellular Therapies, Inc. reported total assets of $1.4 billion, against $728.3 million a year earlier (+87.7%). Source: the 10-K filed with the SEC on Feb 21, 2025. SEC
What are Intra-Cellular Therapies, Inc.'s total liabilities?
As of Dec 31, 2024, Intra-Cellular Therapies, Inc. reported total liabilities of $218.5 million, against $136.9 million a year earlier (+59.6%). Source: the 10-K filed with the SEC on Feb 21, 2025. SEC
What are Intra-Cellular Therapies, Inc.'s cash and cash equivalents?
As of Dec 31, 2024, Intra-Cellular Therapies, Inc. reported cash and cash equivalents of $306.9 million, against $147.8 million a year earlier (+107.7%). Source: the 10-K filed with the SEC on Feb 21, 2025. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1567514&period_type=annual&limit=5"

Information only, not investment advice.